Drug
Regn10597
Regn10597: highest development phase Phase 1/2, developed by Regeneron. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| REGN10597 NCT06413680 | Phase 1/2 | Melanoma |
Latest
No recent events.
Follow Regn10597 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.